JP2009530399A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530399A5
JP2009530399A5 JP2009501576A JP2009501576A JP2009530399A5 JP 2009530399 A5 JP2009530399 A5 JP 2009530399A5 JP 2009501576 A JP2009501576 A JP 2009501576A JP 2009501576 A JP2009501576 A JP 2009501576A JP 2009530399 A5 JP2009530399 A5 JP 2009530399A5
Authority
JP
Japan
Prior art keywords
lower alkyl
substituted
compound
pharmaceutically acceptable
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009501576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/007228 external-priority patent/WO2007111994A2/en
Publication of JP2009530399A publication Critical patent/JP2009530399A/ja
Publication of JP2009530399A5 publication Critical patent/JP2009530399A5/ja
Pending legal-status Critical Current

Links

JP2009501576A 2006-03-22 2007-03-22 Erストレスに関連する疾病の治療のための化合物及び方法 Pending JP2009530399A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US78532806P 2006-03-22 2006-03-22
US78518206P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US78533806P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78533506P 2006-03-22 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (2)

Publication Number Publication Date
JP2009530399A JP2009530399A (ja) 2009-08-27
JP2009530399A5 true JP2009530399A5 (enExample) 2010-05-13

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009501576A Pending JP2009530399A (ja) 2006-03-22 2007-03-22 Erストレスに関連する疾病の治療のための化合物及び方法

Country Status (6)

Country Link
US (1) US20090131384A1 (enExample)
EP (1) EP2001897A2 (enExample)
JP (1) JP2009530399A (enExample)
AU (1) AU2007230991A1 (enExample)
CA (1) CA2681639A1 (enExample)
WO (1) WO2007111994A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047600A1 (en) 2004-10-26 2006-05-04 Dolby Laboratories Licensing Corporation Calculating and adjusting the perceived loudness and/or the perceived spectral balance of an audio signal
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
EP2234954B1 (en) 2007-12-20 2015-02-18 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
AU2009320350B2 (en) * 2008-11-03 2015-09-24 Tufts University Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL2519100T3 (pl) 2009-12-29 2017-09-29 Mapi Pharma Limited Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201505700QA (en) 2010-04-22 2015-08-28 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
JP5709146B2 (ja) 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク. フェニルチオ酢酸化合物、組成物、および、その使用方法
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA114304C2 (uk) 2011-11-03 2017-05-25 Ардеа Біосайєнсіс, Інк. Спосіб зниження сироваткових рівнів сечової кислоти у людини
US9084826B2 (en) 2012-05-01 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists; compositions and method of uses
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
PL2900230T3 (pl) 2012-09-27 2019-02-28 The Children's Medical Center Corporation Związki do leczenia otyłości i sposoby ich zastosowania
CN105431405B (zh) * 2013-03-14 2018-06-01 澳门大学 分离自益智仁的新抗神经变性天然化合物及其全合成
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
HK1243930A1 (zh) * 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
SG11201703997XA (en) 2014-11-26 2017-06-29 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
JP2018505190A (ja) 2015-02-11 2018-02-22 エナンタ ファーマシューティカルズ インコーポレイテッド Fxr/tgr5アゴニストとしての胆汁酸類似体およびその使用方法
RS62110B1 (sr) 2015-03-31 2021-08-31 Enanta Pharm Inc Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
DE102017005884A1 (de) * 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
MX378555B (es) 2016-11-29 2025-03-10 Enanta Pharm Inc Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
DE102018004733A1 (de) * 2018-06-14 2019-12-19 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
CA3227201A1 (en) * 2021-07-26 2023-02-02 Seung Yong Seong Novel compound that inhibits tnf-a generation and inflammasome activity and preparation method therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
AU5322601A (en) * 2000-04-07 2001-10-23 Univ Maryland Bile acid containing prodrugs with enhanced bioavailability
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Similar Documents

Publication Publication Date Title
JP2009530399A5 (enExample)
JP2018518537A5 (enExample)
JP2009530398A5 (enExample)
JP2009524691A5 (enExample)
JP2016510323A5 (enExample)
JP2009529541A5 (enExample)
JP2009543795A5 (enExample)
JP2009533410A5 (enExample)
JP2012504133A5 (enExample)
JP2009535462A5 (enExample)
JP2011513410A5 (enExample)
JP2013532644A5 (enExample)
JP2017538773A5 (enExample)
JP2012504608A5 (enExample)
JP2009536178A5 (enExample)
JP2009535358A5 (enExample)
JP2012506896A5 (enExample)
JP2008521829A5 (enExample)
JP2010522710A5 (enExample)
JP2010523476A5 (enExample)
HRP20150167T4 (hr) Spojevi kao antagonisti bradikinina-b1
JP2012530758A5 (enExample)
JP2018530582A5 (enExample)
JP2007500222A5 (enExample)
JP2008536833A5 (enExample)